

**Supplemental table 6: Demographic and clinical characteristics**

<b>Factor</b>	<b>Normal Pouch (N=7)</b>	<b>Refractory Pouchitis (N=10)</b>	<b>CD (N=13)</b>	<b>p-value</b>
<b>Gender</b>				0.41 <sup>c</sup>
. Male	5(71.4)	4(40.0)	6(46.2)	
. Female	2(28.6)	6(60.0)	7(53.8)	
<b>Caucasian</b>	7(100.0)	10(100.0)	13(100.0)	---
<b>Age at IBD (yrs)</b>	20.4±9.5	27.2±10.5	25.3±13.2	0.49 <sup>a</sup>
<b>Age at pouch (yrs)</b>	32.9±9.4	40.2±10.6	30.4±13.3	0.14 <sup>a</sup>
<b>Age at sample (yrs)</b>	42.7±11.6	51.0±8.8	45.8±15.1	0.39 <sup>a</sup>
<b>IBD duration at pouch (mo)</b>	138.4[43.9,246.8]	150.7[82.8,192.6]	55.0[23.9,83.8]	<b>0.014<sup>b</sup></b>
<b>Reason for pouch</b>				0.89 <sup>d</sup>
. Dysplasia/cancer	2(28.6)	4(40.0)	4(30.8)	
. Refractory disease	5(71.4)	6(60.0)	9(69.2)	
<b>Pouch type</b>				0.99 <sup>d</sup>
. J	7(100.0)	10(100.0)	12(92.3)	
. S	0(0.0)	0(0.0)	1(7.7)	
<b>Days from pouch to ileostomy closure</b>	3.0[0.00,7.3]	3.0[2.8,4.0]	4.4[3.0,8.0]	0.22 <sup>b</sup>
<b>Pre-op diagnosis</b>				0.78 <sup>d</sup>
. UC	6(85.7)	10(100.0)	11(84.6)	
. CD	0(0.0)	0(0.0)	1(7.7)	
. IC	1(14.3)	0(0.0)	1(7.7)	
<b>Extent of IBD pre-op</b>				0.57 <sup>d</sup>
. Extensive colitis,	7(100.0)	9(90.0)	13(100.0)	
. L sided colitis,	0(0.0)	1(10.0)	0(0.0)	
<b>Perianal disease</b>	1(14.3)	0(0.0)	4(30.8)	0.16 <sup>d</sup>
<b>Pre-op biologics</b>	2(28.6)	3(30.0)	2(15.4)	0.64 <sup>d</sup>
<b>Pre-op Immunomodulators</b>	2(28.6)	6(60.0)	1(7.7)	<b>0.019<sup>d</sup></b>
<b>Family history of IBD</b>	1(14.3)	4(40.0)	7(53.8)	0.26 <sup>d</sup>
<b>PSC</b>	1(14.3)	4(40.0)	1(7.7)	0.18 <sup>d</sup>

Values presented as Mean ± SD, Median [P25, P75] or N (column %).

p-values: a=ANOVA, b=Kruskal-Wallis test, c=Pearson's chi-square test, d=Fisher's Exact test.